Drugs / Lymphocytes
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06866158 Background | May → Aug 2024 overdue | diabetic kidney disease | PT. JES Kasih Nusantara Sejahterah | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lymphocytes | “DCL (Dendritic Cells+Lymphocytes) previously matured with S-Protein of SARS-CoV-2.” NCT06866158 ↗ |
| Modality | Cell therapy | “autologous dendritic cell (DC) and lymphocyte administration” NCT06866158 ↗ |